DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C. et al.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol 2011;
12: 735-42
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.